Drug intelligence / Profile preview

BA201

Development stage: Preclinical
Lead developer: T-Cypher Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BA201 is a bispecific T-cell engager (TCE) being developed by T-Cypher Bio for the treatment of solid tumors. The therapeutic candidate is designed to simultaneously target the cancer-testis antigens MAGE-A4 and MAGE-A8 on tumor cells while engaging the CD3 receptor on T cells. This dual-targeting mechanism facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent directed killing of tumor cells expressing MAGE-A4 or MAGE-A8. BA201 is currently in the lead optimization stage of preclinical development.

Other names: BA201-T-Cypher Bio-MAGE-A4-MAGE-A8-CD3-T cell engager-bispecific antibody-Solid tumorsBA-201-T-Cypher Bio-MAGE-A4-MAGE-A8-CD3-T cell engager-bispecific antibody-Solid tumorsBA 201-T-Cypher Bio-MAGE-A4-MAGE-A8-CD3-T cell engager-bispecific antibody-Solid tumors

Targets

MAGEA8 (Melanoma-associated antigen 8)CD3 (T-cell surface glycoprotein CD3)MAGEA4 (Melanoma-associated antigen A4)

Beyond the preview

Go deeper on BA201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA201.

Explore the full profile